FMOC-D-4-甲基苯丙氨酸 | 204260-38-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: FMOC-D-4-甲基苯丙氨酸
• 中文别名: Fmoc-D-4-甲基苯丙氨酸；N-(9-芴甲氧羰酰基)-D-4-甲基苯丙氨酸
• 英文名称: FMOC-(4-methyl-D-phenylalanine)
• 英文别名: Fmoc-DPhe(pCH3)-OH；Fmoc-D-Phe(4-Me)-OH；Fmoc-4-methyl-D-phenylalanine；(2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-methylphenyl)propanoic acid
• CAS: 204260-38-8
• 化学式: C₂₅H₂₃NO₄
• mdl: MFCD00270196
• 分子量: 401.462
• InChiKey: UXLHLZHGQPDMJQ-HSZRJFAPSA-N

物化性质

• 熔点：
  168°C
• 比旋光度：
  31 º (c=1,DMF)
• 沸点：
  629.1±55.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• WGK Germany：
  3
• 海关编码：
  29225090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2~8°C

反应信息

• 作为反应物：
  描述：

  FMOC-D-4-甲基苯丙氨酸 在 哌啶 、 N-羟基丁二酰亚胺 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 9-{3'-deoxy-3'-[(4-methyl-D-phenylalanyl)amino]-β-D-ribofuranosyl}-6-(N,N-dimethylamino)purine
  参考文献：
  名称：

  The Puromycin Route to Assess Stereo- and Regiochemical Constraints on Peptide Bond Formation in Eukaryotic Ribosomes

  摘要：

  We synthesized a series of puromycin analogues to probe the chemical specificity of the ribosome in an intact eukaryotic translation system. These studies reveal that both d-enantiomers and beta-amino acid analogues can be incorporated into protein, and provide a quantitative means to rank natural and unnatural residues. Modeling of a d-amino acid analogue into the 50S ribosomal subunit indicates that steric clash may provide part of the chiral discrimination. The data presented provide one metric of the chiral and regiospecificity of mammalian ribosomes.

  DOI：

  10.1021/ja034817e

文献信息

• Selective Substrates and Activity-Based Probes for Imaging of the Human Constitutive 20S Proteasome in Cells and Blood Samples
  作者：Wioletta Rut、Marcin Poręba、Paulina Kasperkiewicz、Scott J. Snipas、Marcin Drąg

  DOI：10.1021/acs.jmedchem.8b00026

  日期：2018.6.28

  the HyCoSuL approach, we designed and synthesized novel and selective fluorogenic substrates for each of these three constitutive 20S proteasome activities and applied them to assess inhibition of proteasome subunits by MG-132 and a clinically used inhibitor bortezomib. Our results confirm the utility of designed substrates in biochemical assays. Furthermore, selective peptide sequences obtained in this

  蛋白酶体是维持蛋白质稳态的关键酶复合物。蛋白酶体功能紊乱导致包括癌症，自身免疫和神经退行性疾病在内的病理。因此，蛋白酶体构成药物开发的极好的分子靶标。在这里，我们使用HyCoSuL方法为这三个20S组成型蛋白酶体活性中的每一个设计和合成了新颖的选择性荧光底物，并将它们应用于评估MG-132和临床使用的硼替佐米对蛋白酶体亚基的抑制作用。我们的结果证实了设计的底物在生化分析中的实用性。此外，以此方式获得的选择性肽序列用于构建荧光团标记的基于活性的探针，然后用于同时检测HEK-293F细胞和红细胞裂解液中的每个20S组成型蛋白酶体亚基。总体而言，我们描述了一种简单而快速的方法，可用于测量全血样本中20S组成型蛋白酶体的活性，该方法可以早期诊断与异常上调的蛋白酶体活性有关的病理状态。
• Bioactive peptides
  申请人：ALPHARMA AS

  公开号：US20030022821A1

  公开（公告）日：2003-01-30

  The present invention provides a modified lactoferrin peptide which is cytotoxic, 7 to 25 amino acids in length, with three or more cationic residues and which has one or more extra bulky and lipophilic amino acids as compared to the native lactoferrin sequence, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing such peptides, pharmaceutical compositions containing such peptides and use of the peptides as medicaments, particularly as antibacterials or anti-tumoural agents.

  本发明提供一种改性乳铁蛋白肽，其具有细胞毒性，长度为7至25个氨基酸，含有三个或更多阳离子残基，并且与天然乳铁蛋白序列相比，具有一个或多个额外的笨重和亲脂氨基酸，以及其酯、酰胺、盐和环状衍生物，以及制备这些肽的方法、含有这些肽的药物组合物和将这些肽用作药物的用途，特别是作为抗菌或抗肿瘤剂。
• Antimicrobial compounds and formulations
  申请人：——

  公开号：US20030195144A1

  公开（公告）日：2003-10-16

  The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipoophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.

  本发明涉及使用分子制造药物，该分子包括长度为2至35个非氢原子的骨架，至少连接有两个笨重和亲脂性基团，并且具有至少一个阳离子多于阴离子的基团，用作破坏微生物细胞膜的药物，并且涉及使用包括长度为2至35个非氢原子的骨架的分子，该分子共价连接有一个超级笨重和亲脂性基团，包括至少9个非氢原子，并且具有至少两个阳离子多于阴离子的基团，作为膜作用抗微生物药物的用途，以及涉及此类分子的治疗方法，特别是包括肽衍生物和肽类似物的肽。
• Serine protease inhibitors
  申请人：Akzo Nobel N.V.

  公开号：US06218365B1

  公开（公告）日：2001-04-17

  The invention relates to a cornound having formula (I), wherein A, B, X, Y and r are as defined in the description, or a prodrug thereof or a pharnnaceutically acceptable salt thereof. The compounds of the invention have anticoagulant activity and can be used in treating or preventing thrombin-related diseases.

  本发明涉及一种具有式(I)的化合物，其中A、B、X、Y和r如描述中所定义，或其前药或药学上可接受的盐。本发明的化合物具有抗凝血活性，并可用于治疗或预防与凝血酶相关的疾病。
• Inhibition of tumour growth
  申请人：Eliassen Tone Liv

  公开号：US20080019993A1

  公开（公告）日：2008-01-24

  The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoural agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumour growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.

  本发明提供了一种细胞毒性的7至25个氨基酸残基的肽，其中含有三个或更多阳离子残基，其中含有一个或多个非遗传性的臃肿和亲脂性氨基酸，以及它们的酯类、酰胺、盐和环状衍生物，以及制备这些肽的方法、含有它们的药物组合物以及它们作为药物的用途，特别是作为抗菌或抗肿瘤剂。在一个优选方面，本发明提供了利用所述肽在主体中诱导适应性免疫反应以抑制肿瘤生长或建立的方法，以及利用其他溶解剂在主体中诱导适应性免疫反应的方法。